GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.96 USD | +2.14% |
|
+1.82% | -18.58% |
| 07/05 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| 02/05 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 0 M€ | +2.59% | - | |
| 0.35% | 322 M€ | +13.88% | - | |
| 0.35% | 29 M€ | -.--% | - | |
| 0.34% | 1,848 M€ | +18.39% | - | |
| 0.34% | 559 M€ | +14.30% | - | |
| 0.34% | 6 M€ | +17.98% | - | |
| 0.33% | 0 M€ | +6.97% | - | |
| 0.32% | 0 M€ | +4.20% | - | |
| 0.32% | 0 M€ | +18.44% | - | |
| 0.29% | 0 M€ | +8.70% | ||
| 0.29% | 0 M€ | +4.60% | - | |
| 0.28% | 0 M€ | -.--% | ||
| 0.27% | 1 M€ | -.--% | ||
| 0.26% | 7 M€ | +0.11% | - | |
| 0.25% | 0 M€ | +9.42% | ||
| 0.25% | 0 M€ | -.--% | - | |
| 0.25% | 0 M€ | +8.31% | - | |
| 0.25% | 0 M€ | +11.62% | - | |
| 0.25% | 0 M€ | +11.72% | ||
| 0.25% | 205 M€ | -.--% | ||
| 0.24% | 0 M€ | +1.55% | - | |
| 0.23% | 0 M€ | +19.88% | - | |
| 0.21% | 0 M€ | +6.12% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96
USD
Average target price
82.93
USD
Spread / Average Target
+25.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.58% | 80.53B | |
| +30.38% | 695B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 330B | |
| +3.73% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +7.68% | 168B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
